DBT鈥揃IRAC Host 12th Webinar on Cell & Gene Therapy Advancements
21 Apr 2025
2 Min Read
CW Team
The Department of Biotechnology (DBT), Government of India, in collaboration with BIRAC, held the 12th webinar under its Biomanufacturing and Biofoundry Initiative on 17th April 2025. Themed around 鈥淐ell and Gene Therapy鈥�, the session falls under the Precision Biotherapeutics focus of the BioE3 (Biotechnology for Economy, Environment & Employment) Policy, which was approved by the Union Cabinet in August 2024.
With its transformative potential in treating complex and previously incurable diseases, Cell and Gene Therapy (CGT) is a priority area within the BioE3 vision to position India as a global leader in sustainable, high-performance biomanufacturing.
Highlights from the Webinar
Dr Alka Sharma, Senior Adviser, DBT, opened the session by reiterating the BioE3 Policy鈥檚 mission to support green, high-impact biomanufacturing. She emphasised the need for strategic interventions to overcome sectoral challenges and drive growth in CGT innovation and accessibility.
Dr Kamakshi Chaithri, Scientist 鈥楧鈥�, DBT, stressed the urgent need to prioritise this domain, particularly for life-threatening conditions like cancer and rare diseases. She outlined global and national positioning and underlined the DBT鈥檚 ongoing efforts to build a conducive innovation ecosystem for indigenous CGT development.
Dr Debojyoti Chakraborty, Principal Scientist at CSIR鈥揑GIB, discussed cutting-edge gene editing technologies targeting sickle cell anaemia, ocular disorders, and more. He noted the regulatory and manufacturing bottlenecks and the importance of ensuring therapies are affordable and accessible.
Dr Anil Kamat, Head of Clinical Development, Immuneel Therapeutics, spoke on the commercial approval of CAR-T Cell therapy, supported by BIRAC. He discussed scale-up challenges and suggested solutions for improving access, affordability, and availability of CGTs.
The Department of Biotechnology (DBT), Government of India, in collaboration with BIRAC, held the 12th webinar under its Biomanufacturing and Biofoundry Initiative on 17th April 2025. Themed around 鈥淐ell and Gene Therapy鈥�, the session falls under the Precision Biotherapeutics focus of the BioE3 (Biotechnology for Economy, Environment & Employment) Policy, which was approved by the Union Cabinet in August 2024.
With its transformative potential in treating complex and previously incurable diseases, Cell and Gene Therapy (CGT) is a priority area within the BioE3 vision to position India as a global leader in sustainable, high-performance biomanufacturing.
Highlights from the Webinar
Dr Alka Sharma, Senior Adviser, DBT, opened the session by reiterating the BioE3 Policy鈥檚 mission to support green, high-impact biomanufacturing. She emphasised the need for strategic interventions to overcome sectoral challenges and drive growth in CGT innovation and accessibility.
Dr Kamakshi Chaithri, Scientist 鈥楧鈥�, DBT, stressed the urgent need to prioritise this domain, particularly for life-threatening conditions like cancer and rare diseases. She outlined global and national positioning and underlined the DBT鈥檚 ongoing efforts to build a conducive innovation ecosystem for indigenous CGT development.
Dr Debojyoti Chakraborty, Principal Scientist at CSIR鈥揑GIB, discussed cutting-edge gene editing technologies targeting sickle cell anaemia, ocular disorders, and more. He noted the regulatory and manufacturing bottlenecks and the importance of ensuring therapies are affordable and accessible.
Dr Anil Kamat, Head of Clinical Development, Immuneel Therapeutics, spoke on the commercial approval of CAR-T Cell therapy, supported by BIRAC. He discussed scale-up challenges and suggested solutions for improving access, affordability, and availability of CGTs.
Next Story
Inspira Realty Plans 8-10 Redevelopment Projects in Mumbai
Inspira Realty, a leading Mumbai-based developer and a part of Inspira Global, has announced plans to undertake 8鈥�10 new redevelopment projects across the city鈥檚 key western and southern corridors. With this expansion, the firm is poised to exceed its current Gross Development Value (GDV) of Rs 40 billion and drive forward its urban transformation agenda. The company has commenced the financial year with two development agreements signed in Borivali and Santacruz (W) and is actively negotiating further acquisitions. These projects, expected to span a construction area of 4 million sq ..
Next Story
U-Sphere Bags First Private Project with Ceenex in Thiruvananthapuram
U-Sphere, the high-tech construction arm of ULCCS, has secured its first major private sector project: the design and construction of a new training facility for Canada-based Ceenex Global Computer Private Limited in Sasthamangalam, Thiruvananthapuram. The agreement was signed by Remeshan Palery, Director, U-Sphere, and Muhammed Irfan, Director, Ceenex Global. As part of the project, U-Sphere will deliver the core structural framework and building envelope within a fast-tracked seven-month schedule. This facility will serve as a key hub for Ceenex鈥檚 initiatives across e-governance, heal..
Next Story
Godrej Motor Solutions Targets Rs 10 billion Revenue by FY28
The Motor Solutions business of the Godrej Enterprises Group is aiming for Rs 10 billion in revenue by FY28, with 20 per cent of this expected from exports. For FY26, the business is targeting Rs750 crore, driven by demand growth across electric vehicles (EVs), HVAC, pumps, and actuators in both domestic and international markets. Xercsis Marker, EVP & Head, Motor Solutions Business, Godrej Enterprises Group, said, 鈥淲e are strengthening our manufacturing capabilities through significant R&D investments and advanced technology adoption. We continue to invest in t..
